68 results on '"Fung, Chunkit"'
Search Results
2. A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).
3. Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship
4. Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship.
5. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy
6. Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors.
7. Impact of cisplatin-induced hearing loss (CIHL) on patient-reported social and emotional functioning.
8. Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment.
9. Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS).
10. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.
11. Testicular Cancer Survivorship: Looking Back to Move Forward
12. Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.
13. Identifying gaps in the coverage of survivorship care services.
14. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.
15. Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.
16. Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.
17. Surviving Testicular Cancer: The Role of the Contralateral Testicle
18. Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer
19. Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.
20. Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).
21. Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet need.
22. A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results.
23. The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry.
24. Impact of cisplatin-related hearing loss (HL) and tinnitus on patient functioning.
25. Genetic testing patterns for homologous recombination repair (HRR) alterations in patients with metastatic prostate cancer (mPC): An assessment at the University of Rochester (UR).
26. Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).
27. Pretreatment physical activity to predict short- and long-term chemotherapy-induced peripheral neuropathy (CIPN) in a nationwide longitudinal study of paclitaxel for breast cancer.
28. Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.
29. A systematic review of randomized controlled trials (RCTs) of exercise interventions using digital activity trackers (E-DAT) in cancer patients.
30. Effect of exercise on quality of life (QoL) in 198 older patients with cancer: A URCC NCORP nationwide RCT.
31. Feasibility of utilizing a novel mhealth platform to deliver an evidence-based exercise intervention among testicular cancer survivors (TCS).
32. A phase II RCT of high-dose vitamin D supplementation for androgen deprivation therapy (ADT)-induced bone loss among older prostate cancer (PCa) patients.
33. Effects of exercise on dyspnea and cancer-related fatigue in patients with prostate cancer.
34. A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa).
35. Biopsychosocial distress assessment among testicular cancer survivors (TCS) using electronic patient reported outcomes (PROs).
36. Feasibility of an electronic implementation method of an evidence-based exercise intervention among testicular cancer survivors (TCS).
37. An integrative approach to personalized cancer survivorship care at an academic medical center.
38. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer
39. Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.
40. Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients.
41. Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.
42. Reply to S. Alanee et al
43. Psychotropic and stimulant medication (PSM) use among testicular cancer survivors (TCS): A multi-institutional clinical study of 680 patients given cisplatin-based chemotherapy (CHEM) (NCI 1R01 CA157823-02).
44. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study
45. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
46. The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).
47. Association of falls with health related quality of life (HRQOL) in older cancer patients: A population based longitudinal study.
48. Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients.
49. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
50. Prostate Cancer in the Elderly Patient
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.